NCT05656508View on ClinicalTrials.gov

ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

October 29, 2023

Conditions
COVID-19 Vaccine
Interventions
BIOLOGICAL

ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)

2 doses of vaccine with an interval between doses of 28 days. Administration route: Intramuscular (IM) injection

Trial Locations (1)

C1431CAF

Unidad de Investigación Clínica Farmacocinética FP Clinical Pharma en Clínica CIAREC, Buenos Aires

All Listed Sponsors
collaborator

Universidad Nacional de San Martín (UNSAM)

UNKNOWN

collaborator

National Council of Scientific and Technical Research, Argentina

OTHER_GOV

lead

Laboratorio Pablo Cassara S.R.L.

INDUSTRY